Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Reata Pharmaceuticals Inc.

www.reatapharma.com

Latest From Reata Pharmaceuticals Inc.

Finance Watch: Big Money For Big Goals Met By Reata, CRISPR, Karuna

Public Company Edition: Also, Teva sells $2.1bn in notes to pay prior debts. In restructurings, Baudax splits off from Recro, while three firms shift their focus to specific cell therapy programs.

Financing Business Strategies

Reata's Bardoxolone Promises Renal Benefits In Alport Syndrome

Reata is moving ahead with commercial plans as its potential first-in-class Nrf2 activator, bardoxolone methyl, meets primary and secondary endpoints in a first-year interim analysis of the Phase III CARDINAL study in patients with Alport syndrome, an inherited form of chronic kidney disease (CKD).

 

Renal Clinical Trials

Reata Friedreich's Ataxia Drug Shows Late-Stage MOXIe

Analysts have been surprised by positive pivotal data for omaveloxolone, one of Reata's Nrf2 activators – along with bardoxolone – which the company is buying back from AbbVie for $330m.
Rare Diseases Clinical Trials

Deal Watch: GSK Furthers Cancer Gene Therapy Plans Via Lyell Collaboration

GSK hopes the San Francisco biotech’s technology can help its cell therapy pipeline address solid tumors. Avacta partners with ADC on antibody-drug conjugates.

Deals Business Strategies
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
  • Therapeutic Areas
  • Cardiovascular
  • Immune Disorders
  • Inflammation
  • Metabolic Disorders
  • Musculoskeletal & Connective Tissue Disorders
  • Neurology, Nervous System
  • Ophthalmic
  • Renal System
  • Alias(es)
  • Reata Discovery Inc.
  • Ownership
  • Public
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Reata Pharmaceuticals Inc.
  • Senior Management
  • Warren Huff, Pres. & CEO
    Manmeet S Soni, EVP, CFO
    Colin Meyer, MD, EVP, Product Dev. & CMO
    Joel Proksch, PhD, Chief Development Officer
    Dawn C Bir, EVP, Chief Commercial Officer
  • Contact Info
  • Reata Pharmaceuticals Inc.
    Phone: (972) 865-2219
    5320 Legacy Dr.
    Plano, TX 75024
    USA
UsernamePublicRestriction

Register